REGENXBIO (RGNX) Stock Price, News & Analysis

Company Overview

REGENXBIO Inc. is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology. These collaborations leverage the company’s vector engineering expertise to create bespoke gene therapies across multiple therapeutic areas. Through such alliances, REGENXBIO gains access to complementary development resources, while partners benefit from its deep knowledge of AAV vector design and scalable manufacturing processes.

Founded in 2012 and headquartered in Rockville, Maryland, REGENXBIO operates a state‐of‐the‐art manufacturing facility to support both clinical and commercial production of AAV vectors. The company’s leadership team comprises industry veterans with extensive experience in gene therapy research, development and regulatory affairs. REGENXBIO’s scientific advisory board includes academic and clinical experts who guide vector selection, preclinical study design and clinical trial strategy.

REGENXBIO continues to expand its global footprint through clinical trial sites in North America, Europe and Asia, reflecting its commitment to bringing novel gene therapies to patients worldwide. By harnessing the NAV AAV platform’s versatility and safety profile, the company seeks to deliver one‐time treatments that have the potential to transform care for individuals living with severe genetic and ocular diseases.

Key Stats

• Today's Range: $11.63 to $12.26
• 50-Day Range: $5.65 to $11.98
• 52-Week Range: $5.45 to $16.19
• Volume: 1.62 million shs
• Average Volume: 2.29 million shs
• Market Capitalization: $619.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.82
• Consensus Rating: Moderate Buy

REGENXBIO Stock Analysis - MarketRank™

REGENXBIO scored higher than 64% of companies evaluated by MarketBeat, and ranked 264th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

REGENXBIO has a consensus price target of $23.82, representing about 98.8% upside from its current price of $11.98.

Amount of Analyst Coverage

REGENXBIO has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for REGENXBIO are expected to grow in the coming year, from ($3.69) to ($2.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of REGENXBIO is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of REGENXBIO is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

REGENXBIO has a P/B Ratio of 5.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.89% of the float of REGENXBIO has been sold short.

Short Interest Ratio / Days to Cover

REGENXBIO has a short interest ratio ("days to cover") of 6.96.

Change versus previous month

Short interest in REGENXBIO has recently increased by 11.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

REGENXBIO does not currently pay a dividend.

Dividend Growth

REGENXBIO does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.43

News Sentiment

REGENXBIO has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for REGENXBIO this week, compared to 7 articles on an average week.

Search Interest

13 people have searched for RGNX on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $168,705.00 in company stock.

Percentage Held by Insiders

14.22% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/01/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RGNX
• CIK: 1590877
• Web: www.regenxbio.com
• Phone: (240) 552-8181
• Fax: N/A
• Employees: 370
• Year Founded: 2009

Price Target and Rating

• Average Price Target for REGENXBIO: $23.82
• High Price Target: $50.00
• Low Price Target: $12.00
• Potential Upside/Downside: +98.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$193.88 million
• Net Margins: -330.23%
• Pretax Margin: -330.23%
• Return on Equity: -232.50%
• Return on Assets: -61.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.62
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: $170.44 million
• Price / Sales: 3.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.03 per share
• Price / Book: 5.90

Miscellaneous

• Outstanding Shares: 51,700,000
• Free Float: 44,347,000
• Market Cap: $619.37 million
• Optionable: Optionable
• Beta: 1.04